[{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CARA Therapeutics \/ CARA Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ CARA Therapeutics"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"CSL","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CARA Therapeutics \/ CARA Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ CARA Therapeutics"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Maruishi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ CARA Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ CARA Therapeutics"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma Inc","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma Inc"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0.44,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.44,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma Inc","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma Inc"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma Inc","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma Inc"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma Inc","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma Inc"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma Inc","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma Inc"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ HealthCare Royalty","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ HealthCare Royalty"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ CARA Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ CARA Therapeutics"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ CARA Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ CARA Therapeutics"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ CARA Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ CARA Therapeutics"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ CARA Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ CARA Therapeutics"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Tvardi Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"TTI-101","moa":"STAT3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ CARA Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ CARA Therapeutics"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Tvardi Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Merger","leadProduct":"TTI-101","moa":"STAT3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Tvardi Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ Tvardi Therapeutics"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CR845","moa":"Kappa opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CARA Therapeutics \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by CARA Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
